findmyKOL

Robert Motzer, MD

Enriched profile

Genitourinary Medical Oncologist; Section Head, Kidney Cancer, Genitourinary Oncology Service; Jack and Dorothy Byrne Chair in Clinical Oncology · Memorial Sloan Kettering Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusRenal cell carcinoma treatment+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1999–2011

Robert Motzer is Genitourinary Medical Oncologist; Section Head, Kidney Cancer, Genitourinary Oncology Service; Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,588 publications with 124,725 citations (h-index 150); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Robert Motzer as a Highly Cited Researcher (Clinical Medicine, 2016-2024).

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Robert Motzer, MD, is Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center. The public record shows 1,588 publications with 124,725 citations (h-index 150), centered on Renal cell carcinoma treatment, Renal and related cancers, Cancer Genomics and Diagnostics. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 9 companies, 2 NIH-funded awards (1999–2011).

  • Most recent indexed publication: 2026 · Nature reviews. Urology
  • Top research focus: Renal cell carcinoma treatment
  • 18 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Kidney Cancer / RCC12 trialsKidney Neoplasms10 trialsTesticular Germ Cell Tumor6 trialsOvarian / Gynecologic Cancer4 trialsTeratoma2 trialsLung Cancer (NSCLC/SCLC)1 trialBladder / Urothelial Cancer1 trialMelanoma1 trialCentral Nervous System Neoplasms1 trialNervous System Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Renal cell carcinoma treatmentRenal and related cancersCancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersTesticular diseases and treatments

Drugs & molecules

across trials, industry payments and publications
SunitinibClinical trials3Industry payments—Publications21Lenvimageneric · LenvatinibClinical trials—Industry payments7Publications6Keytrudageneric · PembrolizumabClinical trials—Industry payments7Publications4Welireggeneric · BelzutifanClinical trials—Industry payments6Publications1Cabometyxgeneric · CabozantinibClinical trials—Industry payments1Publications5CisplatinClinical trials4Industry payments—Publications1Fotivdageneric · TivozanibClinical trials2Industry payments2Publications—IfosfamideClinical trials3Industry payments—Publications1PaclitaxelClinical trials3Industry payments—Publications1SorafenibClinical trials2Industry payments—Publications1CarboplatinClinical trials1Industry payments—Publications1TemsirolimusClinical trials1Industry payments—Publications1

Works with

trial sponsors and companies reporting payments
AVEO Pharmaceuticals, Inc.Clinical trials2Industry payments2Merck Sharp & Dohme LLCClinical trials—Industry payments23Memorial Sloan Kettering Cancer CenterClinical trials13Industry payments—Merck Sharp & Dohme CorporationClinical trials—Industry payments11Eisai Inc.Clinical trials—Industry payments5Incyte CorporationClinical trials—Industry payments2Alliance for Clinical Trials in OncologyClinical trials1Industry payments—AstraZeneca UK LimitedClinical trials—Industry payments1Eisai Co., Ltd.Clinical trials—Industry payments1EMD SeronoClinical trials1Industry payments—Exelixis Inc.Clinical trials—Industry payments1Ludwig Institute for Cancer ResearchClinical trials1Industry payments—Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,588publications

Distinct works indexed by OpenAlex, matched via ORCID; 61 in PubMed.

124,725citations

Total citations across indexed works.

150h-index

Hirsch index (OpenAlex). i10-index 702.

Clinical & industry

trials, payments and federal funding
18clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 1999–2011

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:

All 18 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 13 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    90.4%
    Kinase inhibitor77.9%
    Cabometyx47%Lenvima40%Everolimus13%
    Part D<11 patients
    Hypoxia-inducible Factor Inhibitor12.5%
    Welireg100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    9.6%
    Corticosteroid9.6%
    Prednisone100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

2 NIH research awards on record, funded 1999–2011 per NIH RePORTER. The latest:

All 10 award records: search, sort and filter.Explore →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 61 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
    5,896 citations2015
    doi.org ↗
  2. 02
    Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    5,758 citations2007
    doi.org ↗
  3. 03
    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    4,647 citations2018
    doi.org ↗
  4. 04
    Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    4,367 citations2019
    doi.org ↗
  5. 05
    Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
    3,647 citations2007
    doi.org ↗
All 1,588 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Toni K. Choueiri359Martin H. Voss311Bernard Escudier242Paul Russo234Brian I. Rini203Darren R. Feldman190George J. Bosl188A. Ari Hakimi172Victor E. Reuter167Dean F. Bajorin150Chung‐Han Lee149Thomas Powles140Joel Sheinfeld140Ying‐Bei Chen136David F. McDermott136Ritesh R. Kotecha135Jonathan Coleman127Maria I. Carlo123Thomas E. Hutson121James J. Hsieh120Frede Donskov108Timothy A. Chan108Alain Ravaud102Michael B. Atkins94Sujata Patil94Camillo Porta93Fengshen Kuo91Ana M. Molina90Sabina Signoretti89Ed Reznik89Nizar M. Tannir87Laurence Albigès80Renzo G. DiNatale79M. Dror Michaelson78Robert A. Figlin77Saby George75Hans J. Hammers75David A. Braun74Andrea Knežević73Viktor Grünwald67

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-motzer-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/robert-motzer-bb28ba68

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Robert-J-Motzer-38816777

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Robert-Motzer-2263656127

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/motzermd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • Other

    ascopost.com/videos/2021-asco-annual-meeting/robert-motzer-on-rcc-quality-of-life-for-patients-treated-with-lenvatinib-based-therapy-vs-sunitinib

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Other

    ascopost.com/videos/esmo-congress-2022/robert-motzer-on-renal-cell-carcinoma-new-results-with-nivolumab-and-ipilimumab

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Other

    reachmd.com/profiles/robert-j-motzer-md/L2312m/biography

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →reachmd.com ↗
  • Other

    urotoday.com/conference-highlights/asco-2026/asco-2026-kidney-cancer/169488-asco-2026-final-analysis-of-the-tinivo-2-phase-3-trial-long-term-outcome-of-tivozanib-in-patients-with-mrcc.html

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    YouTube: Robert Motzer on clear-cell RCC drug resistance / combination regimens

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • YouTube

    YouTube: Dr. Motzer on First-Line Treatment of Metastatic RCC (mirrored on OncLive, Nov 2019)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    YouTube: Dr. Motzer on the Milestone of Immunotherapy in RCC (mirrored on OncLive, Jan 2017)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • Ascopost.com

    ASCO Post video: Robert Motzer on Renal Cell Carcinoma, New Results With Nivolumab and Ipilimumab (ESMO 2022)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Ascopost.com

    ASCO Post video: Robert Motzer on RCC Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib (2021 ASCO Annual Meeting)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Urotoday.com

    UroToday: ASCO 2026 coverage of final analysis of TiNivo-2 phase 3 trial (tivozanib in mRCC), matching JCO 2026 abstract

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
  • Reachmd.com

    ReachMD biography page reproducing MSKCC bio facts

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →reachmd.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Medical Oncology/Hematology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College

    1987
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
  • Residency

    Internal Medicine, North Shore University Hospital/Memorial Sloan Kettering Cancer Center

    1984
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
  • MD

    University of Michigan Medical School

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
  • Board Certified

    Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
  • Board Certified

    Medical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗

Editorial & leadership roles

journal and society appointments

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    201620172018201920202021202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Professor of Medicine

    Department of Medicine, Weill Cornell Medical College

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.